Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Benzodiazepine

or [[:Category:Loop_diuretics|Loop diuretic]]

Use the filters below to narrow your results.

None (9) · Aptiom (1) · Banzel (1) · Briviact (1) · Bumex (1) · Cerebyx (1) · Dalmane (1) · Demadex, Soaanz (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Doral (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Halcion (1) · Lasix (1) · Lexotan (1) · Librium (1) · Luminal (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Sabril (1) · Serax (1) · Tranxene (1) · Versed (1) · Vimpat (1) · Xanax (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (2) · AMPA receptor antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · '"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1)

None (40) · 0.25 mg (1) · 0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) · 10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) · 20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1)

None (40) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 0.5, 1, 2 mg tablets; 0.25 mg/mL IV (1) · 20, 40, 80 mg tablets; 10 mg/mL oral solution; 10 mg/mL IV (1) · 5, 10, 20, 100 mg tablets; 10 mg/mL IV (1)

None (40) · 10 mg/d (1) · 200 mg/d typical practical ceiling (1) · 600 mg/d typical practical ceiling in heart failure (1) · ~10 mg/d typical (1)

None (40) · IM (2) · IV (3) · Oral (4)

None (40) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · IV: 5 minutes; PO: 30-60 minutes (1) · PO 1 hour; IV 10 minutes (1) · PO 30-60 minutes; IV minutes (1)

None (40) · 4-6 hours (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 6-8 hours (1) · IV: ~2 hours; PO: 6-8 hours (1)

None (40) · 1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' (1) · 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' (1) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"' (1)

None (40) · 80-90% oral (1) · ~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' (1) · ~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) · ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' (1)

None (40) · Avoid where possible; can reduce uteroplacental perfusion and produce neonatal electrolyte disturbance. Reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)

None (40) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (3)